Invivomab anti mouse pd 1 cd279 be0273

C57BL/6 mice (7 weeks old) were purchased from Janvier and housed in pathogen-free conditions for one week before experiments. The mice were injected subcutaneously in the right flank with cell lines diluted in 100 µl of PBS. ACB1801 was administered to them with doses of 50, 20, and 10 mg/kg by oral gavage (per os) or 1 mg/kg by an i.p. route. Vehicle treatment was performed using methyl cellulose.
InVivoMab anti-mouse PD-1 (CD279) (BE0273) and InVivoMab rat IgG2a isotype control (BE0089) were purchased from BioXCell (Lebanon, USA), diluted in InVivoPure pH 7.0 Dilution Buffer (IP0070), and administered as indicated in the corresponding figures. Tumor volume (V) was measured using caliper every other day and estimated as follows: V (cm³) = ½ (Length × Width²). Mice were excluded if they did not develop tumors or developed tumors larger than the threshold defined in the approved experimentation protocols (volume > 2000 mm³), as previously reported (15 (link)).

C57BL/6 J mice (male, 4 or 6 weeks old) were purchased from Gempharmatech Co, Ltd. The mice were randomly separated into designated into groups by an independent person. We used 6 or 4 mice per experimental group for all the animal experiments. Control and AKR cells (3 × 10⁶) with PES1 knockdown were injected subcutaneously into each site. For anti-PD1 treatment, when the above mice were subcutaneously injected with AKR cells for 7 days, injection of anti-PD1 (InVivoMAb anti-mouse PD-1 (CD279), BE0273, BioXcell, 2 mg/kg body weight) was performed every 3 days until sacrifice. The tumor size was measured every other day with a Vernier caliper. The tumor volume was calculated according to the following formula: Volume = (length × width²)/2. The animal study was carried out in accordance with approved protocol.